United States:
Moving Past Actavis With Evolving Lifecycle Management Strategies
08 August 2019
Shearman & Sterling LLP
To print this article, all you need is to be registered or login on Mondaq.com.
For nearly two decades, reverse payments have been the perennial
focus in the pharmaceutical industry and among antitrust
professionals. But while courts continue to grapple with the
implications of the Supreme Court's decision in FTC v.
Actavis, Inc., 570 U.S. 136 (2013), more attention is being
brought to pharmaceutical companies' lifecycle management
strategies.
Read this chapter in Shearman &
Sterling's 2019 Antitrust Annual Report, "Moving Past
Actavis with Evolving Lifecycle Management
Strategies"
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Antitrust/Competition Law from United States
US Antitrust Agencies Release Final Revised Merger Guidelines
Goodwin Procter LLP
On December 18, 2023, the Federal Trade Commission and the Antitrust Division of the Department of Justice released the final version of revised Merger Guidelines, a set of principles Agencies use in their review of mergers and acquisitions.
